Akt Inhibition With MK-2206 in Relapsed/Refractory Chronic Lymphocytic Leukemia

Share this content:
Study authors concluded that Akt inhibition with bendamustine and rituximab is a promising strategy for patients in the relapsed/refractory setting.
Study authors concluded that Akt inhibition with bendamustine and rituximab is a promising strategy for patients in the relapsed/refractory setting.

Akt inhibition combined with chemotherapy may be an effective strategy for patients with relapsed or refractory chronic lymphocytic leukemia (CLL), according to a study published in the American Journal of Hematology.1

The activation of Akt — a downstream target of the B cell receptor — is associated with malignant cell survival and resistance to chemotherapy. For this phase 1/2 study (ClinicalTrials.gov Identifier: NCT01369849), researchers evaluated whether Akt inhibition via an investigational drug, MK-2206, would improve patient responses when used with chemotherapy.

The phase 1 part of the study, which included 6 patients, determined a maximum MK-2206 dose of 90 mg orally once per week when combined with bendamustine and rituximab (BR).

In phase 2, which included 13 patients with relapsed or refractory disease, patients received the maximum tolerated dose plus BR. The overall response rate was 92%; median progression-free survival was 16 months.

Common grade 3/4 adverse events included neutropenia, febrile neutropenia, rash, diarrhea, and thrombocytopenia.

RELATED: CD49d Expression Associated With Lymphadenopathy in CLL

The authors concluded that Akt inhibition with BR is a promising strategy for patients in the relapsed/refractory setting. The results “at least compare similarly to” previous efficacy data of BR in relapsed CLL.

Reference

  1. Larsen JT, Shanafelt TD, Leis JF, et al. Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: results from the N1087 Alliance Study. Am J Hematol. In press.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters